Monoclonal antibodies against PD-1, PD-L1 yield significant clinical benefit for lung cancer patients by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized. Here, PDCD1 is linked to lung cancer.